Annual report pursuant to Section 13 and 15(d)

Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)

v3.22.0.1
Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)
3 Months Ended 12 Months Ended
Sep. 03, 2021
USD ($)
item
Dec. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Collaboration and License Agreement      
Number of additional terms | item 2    
Collaboration target basis days 180 days    
Number of days without HSR clearance after effective date before termination 180 days    
Strategic Collaboration and License Agreement      
Collaboration and License Agreement      
Number of types of therapies to be co-developed | item 2    
Initial period of collaborated research 8 years    
Number of additional terms | item 2    
Number of additional years 2 years    
Number of years additional payments are due 5 years    
Upfront payment received   $ 150,000,000  
Amount of additional payments receivable under the research program $ 150,000,000    
Total Number off the Shelf Collaboration Targets | item 5    
Amount of transaction price allocated to performance obligation that has not been recognized as revenue   310,368,000 $ 310,368,000
Amount of transaction price of the agreement at inception   313,600,000 313,600,000
Collaboration Agreement Research Service and Rights, Upfront Payment Earned     150,000,000
Collaboration Agreement Research Service and Rights, Additional Payment Earned     150,000,000
Collaboration Agreement Research Service and Rights, Other Consideration     13,600,000
Strategic Collaboration and License Agreement | Research Service Rights Granted for Initial Off the Shelf Collaboration Targets [Member]      
Collaboration and License Agreement      
Amount of transaction price allocated to performance obligation that has not been recognized as revenue   191,496,000 191,496,000
Strategic Collaboration and License Agreement | Research Service Rights Granted for Personalized Therapies [Member]      
Collaboration and License Agreement      
Amount of transaction price allocated to performance obligation that has not been recognized as revenue   99,079,000 99,079,000
Strategic Collaboration and License Agreement | Material Right to Designate the Additional Off the Shelf Collaboration Target      
Collaboration and License Agreement      
Amount of transaction price allocated to performance obligation that has not been recognized as revenue   13,360,000 13,360,000
Strategic Collaboration and License Agreement | Material Right for First Option Extend the Research Term [Member]      
Collaboration and License Agreement      
Amount of transaction price allocated to performance obligation that has not been recognized as revenue   5,146,000 5,146,000
Strategic Collaboration and License Agreement | Material Right for Second Option Extend the Research Term [Member]      
Collaboration and License Agreement      
Amount of transaction price allocated to performance obligation that has not been recognized as revenue   $ 1,287,000 $ 1,287,000
Development Milestone | Strategic Collaboration and License Agreement | Maximum      
Collaboration and License Agreement      
Milestone payments $ 200,000,000    
Development Milestone - Off The Shelf Member T-cell Therapies | Strategic Collaboration and License Agreement | Maximum      
Collaboration and License Agreement      
Milestone payments 100,000,000    
Research Milestone | Strategic Collaboration and License Agreement | Maximum      
Collaboration and License Agreement      
Milestone payments $ 50,000,000    
Commercialisation Milestone | Strategic Collaboration and License Agreement      
Collaboration and License Agreement      
Total Number off the Shelf Collaboration Targets | item 5    
Commercialisation Milestone | Strategic Collaboration and License Agreement | Maximum      
Collaboration and License Agreement      
Milestone payments $ 1,100,000,000    
Sales Milestone | Strategic Collaboration and License Agreement      
Collaboration and License Agreement      
Number of co-development targets | item 5    
Sales Milestone | Strategic Collaboration and License Agreement | Maximum      
Collaboration and License Agreement      
Milestone payments $ 1,500,000,000    
Regulatory, Sales, And Royalties Milestones | Strategic Collaboration and License Agreement      
Collaboration and License Agreement      
Percentage of profit (loss) sharing ratio 50.00%    
Regulatory, Sales, And Royalties Milestones | Strategic Collaboration and License Agreement | Maximum      
Collaboration and License Agreement      
Milestone payments $ 800,000,000